Search results

...n, Lawrence F Paszat | title = Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study

{{r|Breast cancer}}

...filtrating intraductal carcinoma''', is "a noninvasive (noninfiltrating) [[breast cancer|carcinoma of the breast]] characterized by a proliferation of malignant epi

{{r|Breast cancer}}

...n, Lawrence F Paszat | title = Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study

{{r|Breast cancer}}

...al| author=Esserman L, Shieh Y, Thompson I| title=Rethinking screening for breast cancer and prostate cancer. | journal=JAMA | year= 2009 | volume= 302 | issue= 15 ...Andersson I, Janzon L, Manjer J, Garne JP |title=Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study

...title=Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. | journal=Obstet Gynecol | year=

{{r|Breast cancer}}

...OP, Shapiro S, Tuominen L, Turunen MI| title=Reserpine use in relation to breast cancer. | journal=Lancet | year= 1974 | volume= 2 | issue= 7882 | pages= 675-7 | p ...Curb JD, Hardy RJ, Labarthe DR, Borhani NO, Taylor JO| title=Reserpine and breast cancer in the Hypertension Detection and Follow-Up Program. | journal=Hypertension

...against the ErbB-2 receptor that lengthens remission time in metastatic [[breast cancer]].<ref name="pmid17611206">{{cite journal| author=Hudis CA| title=Trastuzum

...HER2 (Entrez protein) antibody that lengthens remission time in metastatic breast cancer."

===Breast cancer=== ...midlookup?view=short&pmid=19297566&promo=ONFLNS19 |issn=}}</ref> Regarding breast cancer, about 50% of cancers represent overdiagnosis; this fraction is reduced to

...title=Vaginal pH-Balanced Gel for the Control of Atrophic Vaginitis Among Breast Cancer Survivors: A Randomized Controlled Trial. | journal=Obstet Gynecol | year=

...inst the [[ErbB-2 receptor]] that lengthens remission time in metastatic [[breast cancer]]."<ref>{{MeSH|Trastuzumab [Substance Name]}}</ref>

{{r|Breast cancer}}

| title = Ancient chinese remedy shows potential in preventing breast cancer

...drug approved for use with a matching diagnostic test and is used to treat breast cancer in women whose cancer cells express the protein [[HER2]]. ...ing the fastest rates of growth against this background, particularly in [[breast cancer]] treatment. Biopharmaceuticals typically treat sub-sets of the total popu

| journal = Breast Cancer Res. | year = 2007 | volume = 9(Suppl 2) | page= S9.

...nthesis may give rise to new strategies for the prevention or treatment of breast cancer.")